• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BTA
Click for more information
0.00% 57.0¢

BIOTA HOLDINGS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BTARemoval from Official List09/11/12
BTAMerger update, implementation of scheme of arrangement09/11/12
BTABiota receives $4.2m R&D cash incentive07/11/12
BTARelenza September Quarter Royalty01/11/12
BTAInavir sales update31/10/12
BTAAppendix 3Y - Change of Director's Interest Notice31/10/12
BTAAppendix 3Y -Change of Director's Interest Notice31/10/12
BTASuspension from Official QuotationPRICE SENSITIVE30/10/12
BTAMerger update, lodgement of Court orders with ASIC30/10/12
BTAChange in substantial holding30/10/12
BTAAppendix 3B29/10/12
BTASupreme Court of Victoria approves scheme of arrangementPRICE SENSITIVE26/10/12
BTANabi to implement a share consolidation26/10/12
BTAResults of Biota shareholder meetingPRICE SENSITIVE23/10/12
BTABiota Holdings Limited - shareholder meeting23/10/12
BTANabi shareholder meeting resultsPRICE SENSITIVE23/10/12
BTAMerger update, determination of VWAP & share ratiosPRICE SENSITIVE19/10/12
BTAAppendix 3Y - Change of Director's interest Notice17/10/12
BTAAppendix 3Y- Change of Director's Interest Notice03/10/12
BTAAppendix 3Y - Change of Director's Interest Notice02/10/12
BTAChange of Director's Interest Notice27/09/12
BTAChange of Director's Interest Notice25/09/12
BTARelease of Supplementary Explanatory Memorandum21/09/12
BTAAnnual Report to shareholders21/09/12
BTAAmended - Biota and Nabi announce Revised Merger Terms18/09/12
BTABiota and Nabi announce Revised Merger TermsPRICE SENSITIVE18/09/12
BTAUpdate in respect of CEO for Biota PharmaceuticalsPRICE SENSITIVE07/09/12
BTAAppendix 3B24/08/12
BTAAppendix 3B24/08/12
BTAOpen Briefing - CEO on F12 resultsPRICE SENSITIVE22/08/12
BTAPreliminary Final ReportPRICE SENSITIVE22/08/12
BTAInavir prevention study achieves primary endpointPRICE SENSITIVE22/08/12
BTAOpen Briefing - CEO on Nabi MergerPRICE SENSITIVE20/08/12
BTARelease of Scheme Booklet10/08/12
BTABiota Shareholders meeting on proposed merger with Nabi09/08/12
BTAInavir June Quarter (Q4) RoyaltyPRICE SENSITIVE31/07/12
BTARoyalties from Relenza for Q4 and F2012PRICE SENSITIVE26/07/12
BTAShareholder UpdatePRICE SENSITIVE23/07/12
BTAChange in substantial holding06/06/12
BTAChange of Director's Interest Notice22/05/12
BTAAppendix 3B22/05/12
BTAShareholder UpdatePRICE SENSITIVE21/05/12
BTAFinancial update - resubmission16/05/12
BTAFinancial updatePRICE SENSITIVE16/05/12
BTAInavir March Quarter (Q3) RoyaltyPRICE SENSITIVE11/05/12
BTAInavir Phase III prevention study update11/05/12
BTAAppendix 3B02/05/12
BTAAppendix 3B26/04/12
BTARelenza March Quarter RoyaltyPRICE SENSITIVE26/04/12
BTABiota and Nabi Announce Proposed MergerPRICE SENSITIVE23/04/12
BTAHRV Phase IIb Study Achieves Primary EndpointPRICE SENSITIVE28/03/12
BTAAppendix 3B28/03/12
BTAResponse to an ASX price queryPRICE SENSITIVE21/03/12
BTAAppendix 3B09/03/12
BTAOpen Briefing - CEO on 1H Results and OutlookPRICE SENSITIVE15/02/12
BTAHalf Yearly Report and AccountsPRICE SENSITIVE15/02/12
BTAInavir Phase III prevention study detailPRICE SENSITIVE13/02/12
BTARelenza December Quarterly RoyaltyPRICE SENSITIVE08/02/12
BTAInavir Q2 royaltiesPRICE SENSITIVE31/01/12
BTAAppendix 3B22/12/11
BTAChange in substantial holding21/12/11
BTA2011 Annual General Meeting Results29/11/11
BTA2011 AGM Addresses29/11/11
BTAChange in substantial holding08/11/11
BTAInavir sales updatePRICE SENSITIVE31/10/11
BTARelenza September Quarter RoyaltyPRICE SENSITIVE27/10/11
BTANotice of Annual General Meeting/Proxy Form21/10/11
BTAChange in substantial holding04/10/11
BTAAnnual Report to shareholders29/09/11
BTAAppendix 3B16/09/11
BTAOpen Briefing - CEO on F11 results, BARDA Contract18/08/11
BTAAppendix 3B18/08/11
BTAPreliminary Final ReportPRICE SENSITIVE17/08/11
BTA +Change in substantial holding from HHL09/08/11
BTADr John Domagala joins Scientific Advisory Board03/08/11
BTARoyalties from Inavir for Q4 and F2011PRICE SENSITIVE29/07/11
BTARoyalties from Relenza for Q4 and F2011PRICE SENSITIVE27/07/11
BTAChange in substantial holding18/07/11
BTAPhase III prophylaxis trial for CS-8958PRICE SENSITIVE27/06/11
BTAChange in substantial holding15/06/11
BTABiota obtains US$2.9m NIH grant for novel antibacterialPRICE SENSITIVE10/06/11
BTAInavir Royalty for March 2011 quarterPRICE SENSITIVE12/05/11
BTARelenza Royalty for March 2011 quarterPRICE SENSITIVE28/04/11
BTAChange in substantial holding06/04/11
BTABARDA awards major contract to BiotaPRICE SENSITIVE01/04/11
BTABiota appoints Piper Jaffray as financial advisor28/03/11
BTAChange of Director's Interest Notice02/03/11
BTAAppendix 3B02/03/11
BTAChange of Director's Interest Notice23/02/11
BTAOpen Briefing - CEO on Outlook, LANI PotentialPRICE SENSITIVE16/02/11
BTAHalf Year Report and AccountsPRICE SENSITIVE16/02/11
BTARelenza Royalty for December 2010 quarterPRICE SENSITIVE04/02/11
BTAInavir Royalty for December 2010 quarterPRICE SENSITIVE01/02/11
BTAIV zanamivir - Phase III study commences20/01/11
BTAResponse to ASX Price QueryPRICE SENSITIVE10/01/11
BTAAppendix 3B - New issue announcement23/12/10
BTASecurities Trading Policy23/12/10
BTA +Change in substantial holding from HHL16/12/10
BTABecoming a substantial holder08/12/10
AAX +SandP Announces December SP/ASX Rebalance03/12/10
BTARemoval from Official List
09/11/12
BTAMerger update, implementation of scheme of arrangement
09/11/12
BTABiota receives $4.2m R&D cash incentive
07/11/12
BTARelenza September Quarter Royalty
01/11/12
BTAInavir sales update
31/10/12
BTAAppendix 3Y - Change of Director's Interest Notice
31/10/12
BTAAppendix 3Y -Change of Director's Interest Notice
31/10/12
BTASuspension from Official Quotation
30/10/12PRICE SENSITIVE
BTAMerger update, lodgement of Court orders with ASIC
30/10/12
BTAChange in substantial holding
30/10/12
BTAAppendix 3B
29/10/12
BTASupreme Court of Victoria approves scheme of arrangement
26/10/12PRICE SENSITIVE
BTANabi to implement a share consolidation
26/10/12
BTAResults of Biota shareholder meeting
23/10/12PRICE SENSITIVE
BTABiota Holdings Limited - shareholder meeting
23/10/12
BTANabi shareholder meeting results
23/10/12PRICE SENSITIVE
BTAMerger update, determination of VWAP & share ratios
19/10/12PRICE SENSITIVE
BTAAppendix 3Y - Change of Director's interest Notice
17/10/12
BTAAppendix 3Y- Change of Director's Interest Notice
03/10/12
BTAAppendix 3Y - Change of Director's Interest Notice
02/10/12
BTAChange of Director's Interest Notice
27/09/12
BTAChange of Director's Interest Notice
25/09/12
BTARelease of Supplementary Explanatory Memorandum
21/09/12
BTAAnnual Report to shareholders
21/09/12
BTAAmended - Biota and Nabi announce Revised Merger Terms
18/09/12
BTABiota and Nabi announce Revised Merger Terms
18/09/12PRICE SENSITIVE
BTAUpdate in respect of CEO for Biota Pharmaceuticals
07/09/12PRICE SENSITIVE
BTAAppendix 3B
24/08/12
BTAAppendix 3B
24/08/12
BTAOpen Briefing - CEO on F12 results
22/08/12PRICE SENSITIVE
BTAPreliminary Final Report
22/08/12PRICE SENSITIVE
BTAInavir prevention study achieves primary endpoint
22/08/12PRICE SENSITIVE
BTAOpen Briefing - CEO on Nabi Merger
20/08/12PRICE SENSITIVE
BTARelease of Scheme Booklet
10/08/12
BTABiota Shareholders meeting on proposed merger with Nabi
09/08/12
BTAInavir June Quarter (Q4) Royalty
31/07/12PRICE SENSITIVE
BTARoyalties from Relenza for Q4 and F2012
26/07/12PRICE SENSITIVE
BTAShareholder Update
23/07/12PRICE SENSITIVE
BTAChange in substantial holding
06/06/12
BTAChange of Director's Interest Notice
22/05/12
BTAAppendix 3B
22/05/12
BTAShareholder Update
21/05/12PRICE SENSITIVE
BTAFinancial update - resubmission
16/05/12
BTAFinancial update
16/05/12PRICE SENSITIVE
BTAInavir March Quarter (Q3) Royalty
11/05/12PRICE SENSITIVE
BTAInavir Phase III prevention study update
11/05/12
BTAAppendix 3B
02/05/12
BTAAppendix 3B
26/04/12
BTARelenza March Quarter Royalty
26/04/12PRICE SENSITIVE
BTABiota and Nabi Announce Proposed Merger
23/04/12PRICE SENSITIVE
BTAHRV Phase IIb Study Achieves Primary Endpoint
28/03/12PRICE SENSITIVE
BTAAppendix 3B
28/03/12
BTAResponse to an ASX price query
21/03/12PRICE SENSITIVE
BTAAppendix 3B
09/03/12
BTAOpen Briefing - CEO on 1H Results and Outlook
15/02/12PRICE SENSITIVE
BTAHalf Yearly Report and Accounts
15/02/12PRICE SENSITIVE
BTAInavir Phase III prevention study detail
13/02/12PRICE SENSITIVE
BTARelenza December Quarterly Royalty
08/02/12PRICE SENSITIVE
BTAInavir Q2 royalties
31/01/12PRICE SENSITIVE
BTAAppendix 3B
22/12/11
BTAChange in substantial holding
21/12/11
BTA2011 Annual General Meeting Results
29/11/11
BTA2011 AGM Addresses
29/11/11
BTAChange in substantial holding
08/11/11
BTAInavir sales update
31/10/11PRICE SENSITIVE
BTARelenza September Quarter Royalty
27/10/11PRICE SENSITIVE
BTANotice of Annual General Meeting/Proxy Form
21/10/11
BTAChange in substantial holding
04/10/11
BTAAnnual Report to shareholders
29/09/11
BTAAppendix 3B
16/09/11
BTAOpen Briefing - CEO on F11 results, BARDA Contract
18/08/11
BTAAppendix 3B
18/08/11
BTAPreliminary Final Report
17/08/11PRICE SENSITIVE
BTA +Change in substantial holding from HHL
09/08/11
BTADr John Domagala joins Scientific Advisory Board
03/08/11
BTARoyalties from Inavir for Q4 and F2011
29/07/11PRICE SENSITIVE
BTARoyalties from Relenza for Q4 and F2011
27/07/11PRICE SENSITIVE
BTAChange in substantial holding
18/07/11
BTAPhase III prophylaxis trial for CS-8958
27/06/11PRICE SENSITIVE
BTAChange in substantial holding
15/06/11
BTABiota obtains US$2.9m NIH grant for novel antibacterial
10/06/11PRICE SENSITIVE
BTAInavir Royalty for March 2011 quarter
12/05/11PRICE SENSITIVE
BTARelenza Royalty for March 2011 quarter
28/04/11PRICE SENSITIVE
BTAChange in substantial holding
06/04/11
BTABARDA awards major contract to Biota
01/04/11PRICE SENSITIVE
BTABiota appoints Piper Jaffray as financial advisor
28/03/11
BTAChange of Director's Interest Notice
02/03/11
BTAAppendix 3B
02/03/11
BTAChange of Director's Interest Notice
23/02/11
BTAOpen Briefing - CEO on Outlook, LANI Potential
16/02/11PRICE SENSITIVE
BTAHalf Year Report and Accounts
16/02/11PRICE SENSITIVE
BTARelenza Royalty for December 2010 quarter
04/02/11PRICE SENSITIVE
BTAInavir Royalty for December 2010 quarter
01/02/11PRICE SENSITIVE
BTAIV zanamivir - Phase III study commences
20/01/11
BTAResponse to ASX Price Query
10/01/11PRICE SENSITIVE
BTAAppendix 3B - New issue announcement
23/12/10
BTASecurities Trading Policy
23/12/10
BTA +Change in substantial holding from HHL
16/12/10
BTABecoming a substantial holder
08/12/10
AAX +SandP Announces December SP/ASX Rebalance
03/12/10
refresh Created with Sketch. REFRESH
 

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.